QLIF-47. HEALTH RELATED QUALITY OF LIFE AND NEUROLOGICAL DETERIORATION FREE SURVIVAL IN INTELLANCE 2/EORTC TRIAL 1410, A RANDOMIZED PHASE II STUDY ON ABT414 IN RECURRENT EGFR AMPLIFIED GLIOBLASTOMA
Paul M. Clément(Universitair Ziekenhuis Leuven), Vassilis Golfinopoulos(Champalimaud Foundation), Nicolas Whenham(Cliniques Universitaires Saint-Luc), Martin J. van den Bent(Erasmus MC Cancer Institute), Michael Weller(University Hospital of Zurich), Jim Looman(AbbVie (United States)), Filip De Vos(University Medical Center Utrecht), Sarah Nuyens(European Organisation for Research and Treatment of Cancer), Paul Sanghera(The Edgbaston Hospital), Corneel Coens(European Organisation for Research and Treatment of Cancer), Thierry Gorlia(European Organisation for Research and Treatment of Cancer), Jean‐Sébastien Frenel(Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers), Marica Eoli(Fondazione IRCCS Istituto Neurologico Carlo Besta), Enrico Franceschi(Istituto delle Scienze Neurologiche di Bologna), Olivier Chinot(Aix-Marseille Université), Juan Manuel Sepúlveda-Sánchez(Hospital Universitario 12 De Octubre), Ho‐Jin Lee(Seoul National University Hospital), Jan-Peter de Geus(AbbVie (Netherlands)), Maarten Spruyt(European Organisation for Research and Treatment of Cancer), Annemiek Walenkamp(University Medical Center Groningen)
Cited by 2
Related Papers
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
|Nature Reviews Clinical Oncology|2020|1.9k